Guillermo D. Mazzolini He is a medical doctor, graduated from the National University of Rosario (1993), specialist in Clinical Medicine (1996) and in Hepatology, PhD in Medicine (Pathophysiology) from the University of Navarra (2000).
He is currently a Senior Researcher at CONICET. He serves as Dean of the Faculty of Biomedical Sciences at the Universidad Austral and as a tenured professor of Pathophysiology at the same university.
E-Mail: gmazzoli@austral.edu.ar
Our research group functioned as the Gene Therapy Laboratory under the direction of Dr. Mazzolini from 2005, and then, thanks to its growth and international recognition, became an Experimental Hepatology and Gene Therapy Program in 2023.
From its inception, our group's activity has focused on developing strategies to prevent or minimize the consequences of highly lethal liver diseases. To this end, we concentrate on identifying diagnostic markers and therapeutic targets for diseases such as fulminant hepatitis, cirrhosis, and liver and gastrointestinal tumors.
Our group is made up of an interdisciplinary team composed of physicians, biologists, biochemists, biotechnologists and laboratory technicians, which allows us to carry out research projects with an applied and translational approach.
It is important to highlight that our research is enriched by close collaborations not only with the Hepatology and Liver Surgery Unit at Austral University Hospital, but also with other research groups both nationally and internationally. In this regard, our group conducts research with the University of Navarra in Spain (Center for Applied Medical Research); the University of North Carolina, the University of Texas (UT Southwestern Medical Center), and the Mount Sinai School of Medicine in the United States; and the University Hospital of Essen in Germany.
-FATTY LIVER DISEASE AND METABOLISM
This line of research led by the Dr. Catalina Atorrasagasti It seeks to clarify the pathophysiological mechanisms of fatty liver disease, its relationship with
It also investigates other metabolic disorders and how these are affected during aging. Furthermore, it seeks to identify biomarkers for the progression of these diseases.
Dr. Catalina Atorrasagasti She is a biologist, a graduate of the University of Buenos Aires. She obtained her PhD in Biomedical Sciences from the Universidad AustralThanks to her molecular and cellular studies underlying the development of chronic and acute liver diseases (hepatic fibrosis, hepatocellular carcinoma, and fulminant hepatitis), she currently works as an adjunct researcher at the National Scientific and Technical Research Council (CONICET) and as an associate professor of Genetics at the Faculty of Biomedical Sciences of the Universidad Austral and is part of the governing board of the Doctoral program at that Faculty.
E-Mail: catorrasagasti@austral.edu.ar
- LIVER DAMAGE AND REGENERATIVE MEDICINE
This research line, led by Dr. Esteban Juan Fiore, aims to develop therapies for acute liver failure and chronic liver damage (cirrhosis). To this end, it seeks to develop biopharmaceuticals based on stem cells modified through gene therapy, which can be used both to improve patients' quality of life and to preserve ex vivo livers during liver transplantation.
Dr. Esteban Fiore is a Biotechnologist, graduated from the National University of the Littoral (Santa Fe). He later obtained a PhD in Biomedical Sciences from the Universidad AustralThanks to his studies in regenerative medicine strategies for the treatment of liver cirrhosis, he currently works as an adjunct researcher at the National Scientific and Technical Research Council (CONICET) and as an adjunct professor of Immunology in the Medicine program at the Faculty of Biomedical Sciences of the Universidad Austral.
E-Mail: efiore@austral.edu.ar
- LIVER AND GASTROINTESTINAL ONCOLOGY
This line of research, led by Dr. Juan Miguel Bayo Fina, seeks to molecularly characterize liver and gastrointestinal tumors through bioinformatics studies that then allow, through a pharmacogenomic approach, the identification of new therapeutic targets.
Dr. Juan Miguel Bayo Fina holds a degree in Biotechnology from the National University of San Martín (Buenos Aires). He later obtained a PhD in Biomedical Sciences from the Universidad AustralThanks to his studies focused on developing therapeutic strategies for hepatocellular carcinoma based on the use of mesenchymal stromal cells, he subsequently continued his postdoctoral studies at UT Southwestern Medical Center (Dallas, Texas, USA), where he specialized in the study of epigenetic pathways and DNA repair. Currently, he works as an adjunct researcher at the National Scientific and Technical Research Council (CONICET) and as an adjunct professor of Cellular and Molecular Medicine in the Medicine program at the Faculty of Biomedical Sciences of the Universidad Austral.
E-Mail: jbayofina@austral.edu.ar
Fatty Liver Disease and Metabolism
LIVER DAMAGE AND REGENERATIVE MEDICINE
LIVER AND GASTROINTESTINAL ONCOLOGY
